GlassScriptPhysician profile
Nathan Lewis Beebe
NPI 1053331009
$5,740.96
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,032 · 2020: $1,006 · 2021: $1,691 · 2022: $1,011.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $832.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $591.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $551.85 | 2019-2022 | |
| Amarin Pharma, INC. | $433.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $379.93 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $329.42 | 2019-2022 | |
| Amgen INC. | $291.55 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $289.89 | 2019-2022 | |
| Lilly USA, LLC | $273.42 | 2019-2022 | |
| Pfizer INC. | $264.10 | 2019-2021 | |
| Abbvie INC. | $194.99 | 2021-2022 | |
| Abbott Laboratories | $125.50 | 2019-2022 | |
| Glaxosmithkline, LLC. | $124.81 | 2019 | |
| Allergan, INC. | $105.93 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $101.02 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $98.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.99 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.20 | 2022 | |
| Astellas Pharma US INC | $88.25 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $63.01 | 2021-2022 | |
| Daiichi Sankyo INC. | $62.28 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $62.23 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.33 | 2019-2022 | |
| Biogen, INC. | $47.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.73 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $22.69 | 2019 | |
| Esperion Therapeutics, INC. | $17.65 | 2021 | |
| Mylan Specialty L.P. | $17.57 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.54 | 2022 | |
| Eisai INC. | $16.11 | 2021 | |
| Antares Pharma, INC. | $12.17 | 2019 | |
| Nabriva Therapeutics, Plc | $12.04 | 2020 | |
| Dexcom, INC. | $11.73 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Beebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.